Passage BIO, Inc. — Investor Relations & Filings
Filings indexed
414
across all filing types
Latest filing
2026-05-27
Regulatory Filings
Country
US
United States of America
Listing
US
PASG
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on developing therapies for central nervous system (CNS) disorders. The company develops a portfolio of adeno-associated virus (AAV)-delivered therapeutics designed to treat rare, monogenic neurodegenerative diseases by delivering functional genes to patients with mutated or nonfunctional ones. Its lead clinical program, PBFT02, is a gene therapy being evaluated in a Phase 1/2 study for the treatment of Frontotemporal Dementia (FTD) with progranulin gene (GRN) mutations. Passage Bio aims to advance its pipeline to redefine the course of neurodegenerative conditions for patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-27 | English | |
| FORM 8-K | 2026-05-26 | English | |
| 10-Q - Passage BIO, Inc. (0001787297) (Filer) | 2026-05-12 | English | |
| 8-K - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-28 | English | |
| 8-K - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-20 | English | |
| ARS - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-07 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
14 filings
| |||||
| 47845684 | 8-K | 2026-05-27 | English | ||
| 47059730 | FORM 8-K | 2026-05-26 | English | ||
| 45232728 | 10-Q - Passage BIO, Inc. (0001787297) (Filer) | 2026-05-12 | English | ||
| 37959866 | 8-K - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-28 | English | ||
| 34690715 | 8-K - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-20 | English | ||
| 33703026 | ARS - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-07 | English | ||
| 33703035 | DEF 14A - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-07 | English | ||
| 32979094 | 4 - Passage BIO, Inc. (0001787297) (Issuer) | 2026-03-18 | English | ||
| 32898268 | 10-K - PASSAGE BIO, INC. (0001787297) (Filer) | 2026-03-03 | English | ||
| 32898267 | 8-K - PASSAGE BIO, INC. (0001787297) (Filer) | 2026-03-03 | English | ||
| 13203760 | Director's Dealing 2026 | 2026-01-12 | English | ||
| 13203761 | Director's Dealing 2026 | 2026-01-12 | English | ||
| 13203762 | FORM 8-K | 2026-01-12 | English | ||
| 13203764 | Regulatory Filings 2026 | 2026-01-09 | English | ||
|
2025
1 filing
| |||||
| 13203763 | Director's Dealing 2025 | 2025-12-29 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Inotiv, Inc.
A CRO providing nonclinical drug development services and r…
|
NOTV | US | Professional, scientific and te… |
|
INOVIQ LTD
Develops exosome and precision diagnostics for early cancer…
|
IIQ | AU | Professional, scientific and te… |
|
INS BIOSCIENCE BERHAD
R&D, commercialization, distribution of health food supplem…
|
— | MY | Professional, scientific and te… |
|
InSilico Medicine Cayman TopCo
Biotechnology company transforming drug discovery using pro…
|
3696 | KY | Professional, scientific and te… |
|
IntegraGen
Provides genomic services for cancer and rare diseases, tra…
|
ALINT | FR | Professional, scientific and te… |
|
Intellia Therapeutics, Inc.
A clinical-stage genome editing company developing therapeu…
|
NTLA | US | Professional, scientific and te… |
|
InterDigital, Inc.
An R&D company licensing foundational technologies for mobi…
|
IDCC | US | Professional, scientific and te… |
|
IntoCell, Inc.
Develops platform technologies for Antibody-Drug Conjugates…
|
287840 | KR | Professional, scientific and te… |
|
Inventage Lab Inc.
Biopharmaceutical company developing advanced drug delivery…
|
389470 | KR | Professional, scientific and te… |
|
INVENTISBIO CO., LIMITED.
Clinical-stage developer of small molecule drugs for oncolo…
|
688382 | CN | Professional, scientific and te… |
Passage BIO, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34849/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34849 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34849 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34849 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34849}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Passage BIO, Inc. (id: 34849)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.